The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
He was earlier associated with leading industry players like Hindustan Unilever, TATA Communications, Dr. Lal Path Labs, Oncquest and Metropolis Healthcare
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
Key takeaways of recent quarter & conference call highlights
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
Subscribe To Our Newsletter & Stay Updated
